Eur Rev Med Pharmacol Sci 2019; 23 (12): 5382-5391

DOI: 10.26355/eurrev_201906_18207

RUNX3 protects against acute lung injury by inhibiting the JAK2/STAT3 pathway in rats with severe acute pancreatitis

S. Li, H.-Z. Cui, C.-M. Xu, Z.-W. Sun, Z.-K. Tang, H.-L. Chen

Department of General Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China. HailongChen159@163.com


OBJECTIVE: Acute lung injury (ALI) is the most common complication of severe acute pancreatitis (SAP) in the early stage, which causes systemic inflammatory response and organ damage. Human runt-associated transcription factor 3 gene (RUNX3) has been reported to participate in various inflammatory diseases. However, the exact role of RUNX3 in SAP and its-related ALI remains unclear.
MATERIALS AND METHODS: To establish the model of SAP, rats were retrogradely injected with 5% sodium taurocholate (1 mg/kg body weight) into the biliary-pancreatic duct. Cytokine level in serum was measured by ELISA, and the polymorphonuclear neutrophil (PMN) was isolated from rat’s blood 12 h-post SAP induction.
RESULTS: We found RUNX3 expression was significantly decreased with the progression of SAP. Both pancreas damages and cytokine production abilities were reduced in RUXN3-overexpressed SAP rats compared with control rats. Moreover, SAP-associated ALI was also improved upon RUNX3 overexpression in SAP rats. RUNX3 upregulation enhanced PMN apoptosis and inhibited Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) phosphorylation.
CONCLUSIONS: Our study indicates that RUNX3 protects against SAP and SAP-associated ALI through controlling PMN apoptosis and regulating JAK2/STAT3 signaling pathway. RUNX3 could be regarded as a potent therapeutic target in SAP for future studies.

Free PDF Download

To cite this article

S. Li, H.-Z. Cui, C.-M. Xu, Z.-W. Sun, Z.-K. Tang, H.-L. Chen
RUNX3 protects against acute lung injury by inhibiting the JAK2/STAT3 pathway in rats with severe acute pancreatitis

Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 12
Pages: 5382-5391
DOI: 10.26355/eurrev_201906_18207